Our Research Priorities
Drive Strategic Investments
March 15, 2017
MJFF CEO Todd Sherer, PhD, discusses varied work happening around c-Abl inhibitors, an emerging therapeutic target that has shown early promise as a potential disease-modifying therapy.
February 14, 2017
A new study suggests that evaluating levels of a certain protein in the blood may help distinguish Parkinson's from certain atypical parkinsonisms.
UPCOMING FUNDING PROGRAM DEADLINES
Deadline: Pre-Proposals Due: October 19, 2016 - 5pm US ET
Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program supports Parkinson's disease therapeutic development along the pre-clinical and clinical path (both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches).
Deadline: We are no longer accepting pre-proposals at this time.
Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.